Tesamorelin, a human growth hormone releasing factor analogue

Expert Opinion on Investigational Drugs

Volumn 18, Issue 3, 2009, Pages 303-310

  Wang, Ying ^a   Tomlinson, Brian ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Analogue; Growth hormone; Growth hormone deficiency; HIV related lipodystrophy; Human growth hormone releasing factor; Tesamorelin

Indexed keywords

GROWTH HORMONE RELEASING FACTOR DERIVATIVE; PLACEBO; RECOMBINANT GROWTH HORMONE; TESAMORELIN; UNCLASSIFIED DRUG; DRUG DERIVATIVE; GROWTH HORMONE RELEASING FACTOR;

CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GROWTH HORMONE DEFICIENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAABDOMINAL FAT; LIPODYSTROPHY; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT; CHEMISTRY; DRUG TOLERANCE; METABOLISM; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DRUG TOLERANCE; GROWTH HORMONE-RELEASING HORMONE; HUMANS; TREATMENT OUTCOME;

EID: 67449093468     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780802707658     Document Type: Review

References (61)

1. Lin-Su K, Wajnrajch MP. Growth Hormone Releasing Hormone (GHRH) and the GHRH Receptor. Rev Endocr Metab Disord 2002;3 (4):313-323
2. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998;19:717-797 •• Describes the mechanism of growth hormone secretion. (Pubitemid 128506521)
3. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-660 (Pubitemid 129516334)
4. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000;85:4908-4911 (Pubitemid 32157685)
5. Zadik Z, Chalew SA, McCarter RJ Jr, et al. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab 1985;60:513-516 (Pubitemid 15133853)
6. Veldhuis JD, Bowers CY. Human GH pulsatility: an ensemble property regulated by age and gender. J Endocrinol Invest 2003;26:799-813 (Pubitemid 38049162)
7. van den Berg G, Veldhuis JD, Frolich M, et al. An amplitude-specific divergence in the pulsatile mode of GH secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab 1996;81:2460-2466 (Pubitemid 26240261)
8. Ho KKY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987;64:51-58 (Pubitemid 17015877)
9. Coiro V, Volpi R, Bertoni P, et al. Effect of potentiation of cholinergic tone by pyridostigmine on the GH response to GHRH in elderly men. Gerontology 2002;38:217-222
10. Veldhuis JD, Iranmanesh A. Physiological regulation of the human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis: predominant impact of age, obesity, gonadal function, and sleep. Sleep 1996;19:S221-4 (Pubitemid 27138534)
11. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, et al. Serum insulin-like growth factor I in a random population of men and women: Relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf) 1996;41:2209-2215 (Pubitemid 24278330)
12. Savine R, Sonksen P. Growth hormone-hormone replacement for the somatopause? Horm Res 2000;53 (Suppl 3):37-41
13. Young A. Muscle function in old age. New Iss Neurosci 1998;I:141-156
14. Skelton DA, Grieg CA, Davies JM, et al. Strength, power and related functional ability of healthy people aged 60-89 years. Age Ageing 1994;23:371-377 (Pubitemid 24292161)
15. Bohannon RW. Comfortable and maximum walking speed of adults aged 20- 79 years: reference values and determinants. Age Ageing 1997;26:15-19 (Pubitemid 27153910)
16. Ayuk J, Sheppard MC. Growth hormone and its disorders. Postgrad Med J 2006;82(963):24-30 (Pubitemid 43111799)
17. Ottosson M, Vikman-Adolfsson K, Enerback S, et al. Growth hormone inhibits lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 1995;80(3):936-941
18. Schwarz JM, Mulligan K, Lee J, et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2002;87(2):942 (Pubitemid 34158275)
19. Brandou F, Aloulou I, Razimbaud A, et al. Lower ability to oxidize lipids in adult patients with growth hormone (GH) deficiency: reversal under GH treatment. Clin Endocrinol (Oxf) 2006;65(4):423-428 (Pubitemid 44414263)
20. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285-288 (Pubitemid 20229130)
21. Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996;81:1169-1172
22. Bulow B, Hagmart L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 1997;46:75-81 (Pubitemid 27072849)
23. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357:425-431 (Pubitemid 32156141)
24. Van der Lely AJ. Justified and unjustified use of growth hormone. Postgrad Med J 2004;80(948):577-580 (Pubitemid 39389407)
25. Khorram O. Use of growth hormone and growth hormone secretagogues in aging: help or harm. Clin Obstet Gynecol 2001;44(4):893-901 (Pubitemid 33115835)
26. Carr A, Samaras K, Thoridottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;53:2093-2099 (Pubitemid 29278477)
27. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465-471
28. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352(1):48-62 (Pubitemid 40075680)
29. Grinspoon S, Gelato M. The rational use of growth hormone in HIV-infected patients. J Clin Endocrinol Metab 2001;86:3478-3479 (Pubitemid 32755933)
30. D'Amico S, Shi J, Sekhar RV, et al. Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome. Am J Clin Nutr 2006;84(1):204-211 (Pubitemid 44699187)
31. Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 2008;300(5):509-519
32. Chappel S. Can GHRH or GH secretagogues re-initiate pituitary GH pulsatility? Clin Endocrinol 1999;50(5):547-556
33. Corpas E, Harman SM, Pineyro MA, et al. Continuous subcutaneous infusions of growth hormona (GH) releasing hormone 1-44 for 14 days incrase GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1993;76(1):1134-1138 (Pubitemid 23027567)
34. Root AW, Root MJ. Clinical pharmacology of human growth hormone and its secretagogues. Curr Drug Targets Immune Endocr Metabol Disord 2002;2(1):27-52
35. Forhman LA, Downs TR, Williams TC, et al. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. Am J Clin Invest 1986;78(4):906-913 (Pubitemid 17177069)
36. Abribat T, Chapdelaine A, Gravel D, et al. TH 9507, a new growth hormone-releasing factor (GFR) analogue, is a powerful insulin-like growth factor-1(IGF-1) inducer in 50-60 year old healthy subjects: A 7-day randomized multidose study. Endocr Soc 2001;83:292 • Important Phase I study of tesamorelin evaluating its efficacy of stimulating GH.
37. Falutz J, Allas S, Kotler D, Thompson M. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 2005;19(12):1279-1287 • Important Phase I study of tesamorelin evaluating its safety and efficacy in patients with HIV-related lipodystrophy. (Pubitemid 41224897)
38. Schols AMWJ, Maltais F, O'Donnell DE, et al. Anabolic effects and safety assessments of TH9507, a growth hormone releasing factor (GRF) analog, in patients with COPD-associated wasting. Eur Respir J 2004;24(48):P1888
39. Tomlinson B. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. Curr Opin Investig Drugs 2006;7(10):936-945 • Overview of tesamorelin. (Pubitemid 44613722)
40. Thorner M, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab 1996;81(3):1189-1196 (Pubitemid 26083992)
41. Chen RG, Shen YN, Yei J, et al. A comparative study of growth hormone (GH) and GH-releasing hormone (1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta Paediatr Suppl 1993;388:32-35
42. Neyzi O, Yordam N, Ocal G, et al. Growth response to growth hormone-releasing hormone (1-29)-NH2 compared with growth hormone. Acta Paediatr Suppl 1993;388:16-21
43. Broglio F, Benso A, Gottero C, et al. Endocrine activities of alexamorelin (Ala-His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2), a synthetic GH secretagogue, in humans. Eur J Endocrinol 2000;143(3):419-425
44. Bisi G, Podio V, Valetto MR, et al. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J Endocrinol Invest 1999;22(4):266-272 (Pubitemid 29224325)
45. LAB International Inc. Company. Available from: http://www.labinc.ca/ products.html [Accessed 30 May 2008]
46. Bohlen P, Esch F, Brazeau B, et al. Isolation and characterization of the porcine hypothalamic growth hormone releasing factor. Biochem Biophys Res Commun 1983;116:726-734 (Pubitemid 14242792)
47. Bohlen P, Wehrenberg WP, Esch F, et al. Rat hypothalamic growth hormone-releasing factor: isolation, sequence analysis and total synthesis. Biochem Biohys Res Commun 1984;125:1005-1012 (Pubitemid 15152893)
48. Brazeau P, Bohlen P, Esch F, et al. Growth hormone-releasing factor from ovine and caprine hypothalamus: isolation, sequence analysis and total synthesis. Biochem Biophys Res Commun 1984;125:606-614 (Pubitemid 15155740)
49. Campbell RM, Bongers J, Felix AM. Rational design, synthesis, and biological evaluation of novel growth hormone-releasing factor analogues. Biopolymers 1995;37:67-88
50. Dubreuil P, Desevaux C. Growth hormone-releasing factor: structural modification and protection for more potent analogues. Comb Chem High Throughput Screen 2006;9:171-174 •• Describes the chemistry of growth hormone-releasing factor.
51. Larocque A, Vaillancourt C, Abribat T, et al. Anchoring rigid hydrophobic chains to stabilize growth hormone-releasing factor [abstract 382]. 17th American Peptide Symposium, San Diego, USA, 9- 14 June 2001, Abstract book. p. 365.
52. Proc Am Pept Symp 2001;17
53. Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol 2007;100(1):49-58 (Pubitemid 46051443)
54. High KA, Gritsas A, Tsikos T, et al. Assessment of ex vivo DPP IV proteolytic cleavage of TH9507 in rat, dog and human plasma by LC/MS [abstract]. Proc Asms Conf Mass Spect Allied Topics San Antonio, TX, USA; 2005
55. Jansen M, Darby I, Abribat T, et al. Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. Int J Pharm 2004;276(1-2):75-81 (Pubitemid 38542990)
56. Allas S, Lussier B, Chapdelaine A, et al. Endocrine and metabolic effects of TH9507, a growth hormone-releasing factor (GRF) analogue, in elderly male and female subjects [abstract 382]. ENDO 2004, 86th Annual Meeting of The Endocrine Society, New Orleans, USA, 16-19 June 2004. Endocr Soc 2004;86
57. Alexandre B, Allas S, De Villers A, et al. Effects of gender on the insulin-like growth factor-1 response to repeated administration of TH9507, a long acting growth-hormone releasing factor analogue [abstract 85]. 85th Annual Meeting of the Endocrine Society, Philadelphia, USA, 18 June 2003. Endocr Soc 2003;85
58. Maltais F, O'Donnell DE, Schols AMWJ, et al. Effect of TH9507, a growth hormone releasing factor (GFR) analog, on functional performance in patients with COPD [Abstract]. Eur Respir J 2004;24(48):P1603
59. Maltais F, O'Donnell DE, Schols AMWJ, et al. Effect of TH9507, a growth hormone-releasing factor (GFR) analogue, on health-related quality of life and respiratory muscle function in patients with COPD-associated wasting [abstract 4342]. Proc Am Thorac Soc 2005
60. Falutz J, Allas S, Blot K, et al. Metabolic effects of growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357(23):2359- 2370 • Important Phase III study of tesamorelin evaluating its long-term safety and efficacy in patients with HIV-related LDS. (Pubitemid 350223390)
61. Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol 2007;100(1):49-58 (Pubitemid 46051443)